Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Biostar Pharmaceuticals, Inc. | ex32-2.htm |
EX-32.1 - EX-32.1 - Biostar Pharmaceuticals, Inc. | ex32-1.htm |
EX-31.2 - EX-31.2 - Biostar Pharmaceuticals, Inc. | ex31-2.htm |
EX-31.1 - EX-31.1 - Biostar Pharmaceuticals, Inc. | ex31-1.htm |
EX-23.3 - EX-23.3 - Biostar Pharmaceuticals, Inc. | ex23-3.htm |
EX-23.2 - EX-23.2 - Biostar Pharmaceuticals, Inc. | ex23-2.htm |
EX-21 - EX-21 - Biostar Pharmaceuticals, Inc. | ex21.htm |
10-K - 10-K - Biostar Pharmaceuticals, Inc. | biostarpharma10k123116.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
To the Board of Directors of
Biostar Pharmaceuticals, Inc.
We hereby consent to the incorporation by reference of our report dated April 13, 2017 with respect of the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for the years ended December 31, 2016 and 2015 into the Annual Report on Form 10-K of Biostar Pharmaceuticals, Inc. for the year ended December 31, 2016, which report will be filed with the U.S. Securities and Exchange Commission on April 13, 2017.
/s/Mazars CPA Limited
|
|
Mazars CPA Limited
Certified Public Accountants
|
|
Hong Kong
|
|
April 13, 2017
|